Infectious diseases are significant causes of human mortality, morbidity, and economic loss. Although effective antimicrobial agents are available for treating bacterial infections, as are limited agents for viral, fungal, and parasitic infections, many diseases are still very difficult to treat effectively and may present serious health concerns. The emergence of drug resistance among common pathogens continues to render ineffective many previously frontline therapies, and the use of many drugs is often limited by toxicity concerns. Emergence of diseases caused by new or drug-resistant pathogens demands more effective drugs. However, current advances in chemistry, bioinformatics, and structural biology should make it possible to discover or design novel anti-infective agents that target specific functions required for pathogen growth and pathogenesis (http://www3.niaid.nih.gov/about/organization/dmid/overview.htm).
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Julander, J. G., Siddharthan, V., Blatt, L. M., Schafer, K., Sidwell, R. W., and Morrey, J. D. (2007) Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model, Antiviral Res., 73(2), 140–146.
Randhawa, P., Farasati, N.A., Shapiro, R., and Hostetler, K. Y. (2006) Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro, Antimicrob. Agents Chemother., 50, 1564–1566.
Noah, J. W., Severson, W., Noah, D. L., Rasmussen, L., White, E. L., and Jonsson, C.B. (2006) A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals, Antiviral Res., 73(1), 50–59.
Malakhov, M. P., Aschenbrenner, L. M., Smee, D. F., Wandersee, M. K., Sidwell, R. W., Gubareva, L. V., Mishin, V. P., Hayden, F. G., Kim, D. H., Ing, A., Campbell, E. R., Yu, M., and Fang, F. (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection, Antimicrob. Agents Chemother., 50, 1470–1479.
Prichard, M. N., Keith, K. A., Quenelle, D. C., and Kern, E. R. (2006) Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections, Antimicrob Agents Chemother., 50, 1336–1341.
Vilcheze, C., Wang, F., Arai, M., Hazbon, M. H., Colangeli, R., Kremer, L., Weisbrod, T. R., Alland, D., Sacchettini, J. C., and Jacobs, W. R. Jr. (2006) Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid, Nat. Med., 12(9), 1027–1029.
Deziel, M. R., Heine, H., Louie, A., Kao, M., Byrne, W. R., Basset, J., Miller, L., Bush, K., Kelly, M., and Drusano, G. L. (2005) Effective antimicrobial regimens for use in humans of Bacillus anthracis infections and postexposure prophylaxis, Antimicrob. Agents Chemother. 49, 5099–5106.
Kumar, P., Lee, S. K., Shankar, P., and Swamy, M. (2006) A single siRNA suppresses fatal encephalitis induced by two different flaviviruses, PLoS Med., 3(4), e96.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Georgiev, V.S. (2009). Drug Development Research. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_26
Download citation
DOI: https://doi.org/10.1007/978-1-60327-297-1_26
Publisher Name: Humana Press
Print ISBN: 978-1-60327-296-4
Online ISBN: 978-1-60327-297-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)